Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville

Lonza to Provide Exclusive Manufacturing Services to Regenicin for new Proprietary Skin Production Technology

NEW YORK, August 18, 2010 - Regenicin, Inc. (OTC Bulletin Board: WDSTD), a development stage
biotechnology company, announced today that it has completed an initial
US$3.25 million funding in conjunction with its acquisition of a worldwide
exclusive license to know-how technology controlled by Lonza Walkersville
("Lonza Agreement"). Lonza Walkersville is a subsidiary of Lonza Group Ltd.
(SIX: LONN), one of the world's leading suppliers to the pharmaceutical,
healthcare and life science industries and the largest cell therapy
manufacturer in the world.

The Lonza Agreement provides Regenicin with the worldwide marketing
rights to a proprietary tissue-engineered skin substitute technology intended
to restore the qualities of healthy human skin for use in the treatment of
burns, chronic wounds and a variety of plastic surgery procedures.
Regenicin's management team intends to use its expertise, with the assistance
of Lonza Walkersville, to further enhance its capabilities and seek approval
by the U.S. Food and Drug Administration for commercial sale. Regenicin plans
to seek marketing approval for this revolutionary product throughout the
world under the brand name PermaDerm(TM).

Pursuant to the Lonza Agreement, Lonza will retain exclusive
manufacturing rights for PermaDerm(TM) products. Additionally, a license to
the patent rights and related key intellectual property comprising the
technology, developed at the University of California, University of
Colorado, the University of Cincinnati and Shriners Hospitals for Children,
may be acquired by Regenicin if FDA approval is obtained.

Regenicin secured the initial financing through a combination of
convertible loans and a private placement of its common stock with several
major institutions and accredited investors. NewOak Capital, Inc. and Smith
Point, Ltd. acted as co-placement agents.

"We are excited to have secured the funds necessary to help us complete
this licensing agreement with Lonza and to prepare to advance this important
technology to commercialization. We believe Regenicin is now poised to
address a significant unmet medical need as PermaDerm(TM) is the only
tissue-engineered skin prepared from a patient's own skin cells," Randall
McCoy, Chief Executive Officer of Regenicin said. "The technology combines
cultured epithelium with a collagen-fibroblast implant that produces a skin
substitute that contains both epidermal and dermal components. This model has
been shown in preclinical studies to generate a functional skin barrier,
which is an important step towards realizing the potential of regenerative
medicine."

About Regenicin, Inc.

Regenicin, Inc. is a development stage company focusing on
next-generation tissue-engineered skin substitutes to restore the qualities
of healthy human skin. Regenicin is a publicly traded company, with
headquarters in Little Falls, NJ. Additional information can be found in the
company's filings with the Securities and Exchange Commission located at
www.sec.gov.

Jay Strell of Sunshine, Sachs and Associates, +1-212-691-2800, strell at sunshinesachs.com